Skip Nav Destination
President's Column
Let’s Grow Together in 2025
January 9, 2025
"I'm excited to see how ASH soars ever higher in 2025," shares new ASH President Belinda Avalos, MD.
Idiopathic Multicentric Castleman Disease
How do we improve the diagnosis and outcome of Castleman disease?
Minimal Residual Disease as a Primary Endpoint in Multiple Myeloma
While minimal residual disease testing has clear prognostic value, its utility in supporting treatment decisions for an individual patient at the bedside remains unclear.
Honoring a Champion of ASH and Hematology
Hematology lost a great leader and champion with the untimely passing of Samuel Silver, MD, PhD.
